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INTRODUCTION
Behçets disease (BD) is classified as variable vessel vasculitis 
that affects small, medium, and large-sized arteries or veins 
based on the 2012 Chapel Hill Consensus Conference Nomen-
clature of Vasculitis (the 2012 CHCC definitions).1 BD is a chron-
ic and multi-systemic syndrome that manifests with hallmark 
features of recurrent oral and genital ulcers and skin lesions. It 
can also affect ocular, cardiovascular, neurological, gastrointes-
tinal (GI), and musculoskeletal systems.2 In addition to hetero-
geneous and multiorgan manifestations in BD, there is no uni-
versally accepted diagnostic test for BD; thus, diagnosis of BD 
has heavily relied on the identification of several clinical fea-
tures and the exclusion of other medical conditions.3 For these 
reasons, various clinical classification criteria for BD have been 
suggested and validated, among which two are the most wide-
ly recognized: The International Study Group (ISG) Criteria in 
1990 (the 1990 ISG criteria) and the revised version of the Inter-
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national Criteria for Behçet’s Disease (ICBD) in 2014 (the 2014 
ICBD criteria).4,5 There are two obvious differences between the 
two criteria: unlike the 1990 ISG criteria, the 2014 ICBD criteria 
uses a scoring system and includes vascular and neurological 
manifestations as its point-rating items.6 
Since many other inflammatory diseases may share some 
clinical features of BD, such as systemic lupus erythematosus, 
inflammatory bowel disease, sarcoidosis, and antineutrophil 
cytoplasmic antibody (ANCA)-associated vasculitis (AAV), 
they should be distinguished from BD.3 Among these medical 
conditions, AAV, which affects small-sized vessels, has overlap-
ping clinical features with BD; however, it can be classified and 
distinguished from BD by the 2012 CHCC definitions and the 
classification algorithm proposed by the European Medicine 
Agency in 2007 (the 2007 EMA algorithm).1,7 Detection of ANCA 
against myeloperoxidase (MPO) and proteinase 3 (PR3) also 
plays a supportive role in distinguishing the two diseases.8 Nev-
ertheless, ANCA positivity cannot be an absolute marker to dis-
criminate BD from AAV, because a few cases of ANCA positiv-
ity in BD have been previously reported: one of the previous 
case-series studies also reported that ANCA-positive patients 
with BD did not exhibit any arterial or venous thrombosis and 
arterial aneurysms.9 However, there has been no extensive study 
to explore the clinical significance of ANCA, particularly in the 
context of vascular manifestations, on a large number of pa-
tients with BD. In this study, we investigated whether ANCA 
positivity might be associated with cross-sectional vascular 
manifestations at diagnosis of BD and whether ANCA positiv-
ity could be assessed as a potential predictor of poor outcomes, 




We retrospectively reviewed the medical records of 1060 pa-
tients with BD who were selected based on the following in-
clusion and exclusion criteria: 1) patients who were initially 
diagnosed with BD the Division of Rheumatology, the Depart-
ment of Internal Medicine, Yonsei University College of Medi-
cine, Severance Hospital, from March 1990 to August 2019; 2) 
patients with BD as the primary diagnosis, which was confirmed 
by the 10th revised International Classification Diseases codes 
recorded in the clinical data repository (CDR) of Severance Hos-
pital; 3) patients who had the results for ANCA tests; 4) patients 
who had medical records complete enough to collect and re-
view clinical and laboratory data at diagnosis and to apply the 
two BD diagnosis criteria; 5) patients who had ANCA, but were 
not classified with AAV based on both the 2007 EMA algorithm 
and the 2012 CHCC definitions;1,7 6) patients who, at diagnosis, 
had no serious medical conditions mimicking BD, such as au-
toimmune diseases, inflammatory bowel diseases, and system-
ic vasculitides other than BD;3 and 7) patients who had been fol-
lowed up for more than 6 months until the time of inclusion 
in this study. For reclassification, the 1990 ISG criteria and the 
2014 ICBD criteria were applied to all of them. Finally, 808 of 
1060 BD patients could be reclassified with BD based on the 
2014 ICBD criteria.5 In addition, 588 of the 1060 BD patients 
could be reclassified with BD based on the 1990 ISG criteria.4 
All patients who fulfilled the 1990 ISG criteria met the 2014 ICBD 
criteria (Supplementary Fig. 1, only online). No ANCA-positive 
BD patients were reclassified as AAV (Supplementary Table 1, 
only online). All procedures performed in studies involving hu-
man participants were conducted in accordance with the eth-
ical standards of institutional and/or national research com-
mittees and with the 1964 Helsinki Declaration and its later 
amendments or comparable ethical standards. This study was 
approved by the Institutional Review Board (IRB) of Severance 
Hospital (4-2019-1331). The need for written informed consent 
from the patients was waived by the approving IRB, as this was 
a retrospective study.
ANCA tests 
ANCA tests were conducted either or both by indirect immu-
nofluorescence assays (IIA) for perinuclear (P)-ANCA and cy-
toplasmic (C)-ANCA and antigen-specific assays for MPO-AN-
CA and PR3-ANCA, and the results were also included in the 
medical records. First, we used the IIA as the primary screen-
ing method for ANCA.10 The antigen-specific assays for MPO-
ANCA and PR3-ANCA were performed by using novel anchor 
coated highly sensitive Phadia ELiA (Thermo Fisher Scientific/
Phadia, Freiburg, Germany) that contains human native anti-
gens, and its levels were measured with a Phadia250 analyzer. 
For those patients who had no results from antigen-specific as-
says, but had ANCA positivity by the IIA, we considered them 
to have MPO-ANCA (or P-ANCA) or PR3-ANCA (or C-ANCA). 
Clinical and laboratory data
We collected demographic data regarding age at diagnosis and 
sex. We obtained the results from ANCA tests that were per-
formed within 6 weeks before and after diagnosis. We reviewed 
any clinical manifestations related to the criteria for BD and 
comorbidities, such as diabetes mellitus, hypertension, dyslip-
idemia, aortic valve replacement, percutaneous coronary in-
tervention, and other vascular intervention at the time of di-
agnosis, and then we counted the number of patients having 
each clinical manifestation. During follow up, all-cause mor-
tality, cerebral vascular accident, acute coronary syndrome, 
deep vein thrombosis (DVT), GI involvement, and ocular in-
volvement were evaluated as adverse outcomes. The frequen-
cy of the use of six medications [glucocorticoid, colchicine, aza-
thioprine, methotrexate, cyclosporine, and anti-tumor necrosis 
factor alphas inhibitor (TNF-α blockade)] were also reviewed. 
The follow-up duration was defined as the period between the 
date of diagnosis of BD and the date of the last visit for surviving 
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patients. For the deceased patients, the follow-up duration was 
defined as the period between the diagnosis of BD and the time 
of death. For patients who had any adverse outcomes, it was 
defined as the period starting from the diagnosis of BD until an 
adverse outcome appeared. 
Sites and patterns of vascular manifestations at 
diagnosis
We investigated BD patients for any sites and/or patterns of 
vascular involvement that includes arterial or venous throm-
bosis and arterial aneurysms. We categorized 8 sites as follows: 
thrombosis at the lower extremities; vena cava thrombosis; ce-
rebral venous sinus thrombosis; pulmonary artery involvement; 
intracardiac thrombosis; aorta involvement; and extra-pulmo-
nary artery involvement, including the lower extremities, upper 
extremities, and visceral arteries.11
Statistical analyses
All statistical analyses were conducted using SPSS software (ver-
sion 23 for Windows; IBM Corp., Armonk, NY, USA). Continu-
ous variables are expressed as medians (interquartile range), 
and categorical variables are expressed as numbers and per-
centages. Significant differences in categorical variables be-
tween the two groups were analyzed using the chi-square and 
Fisher’s exact tests. Significant differences in continuous vari-
ables between the two groups were compared using the Mann-
Whitney test. Comparisons of cumulative overall survival rate 
and adverse outcome-free survival rates between two groups 
were analyzed by the Kaplan-Meier survival analysis. p values 
less than 0.05 were considered statistically significant.
RESULTS
Characteristics of the 808 BD patients based on the 
2014 ICBD criteria
The baseline and follow-up characteristics of the 808 BD pa-
tients who met the 2014 ICBD criteria are described in Table 1. 
At the time of diagnosis of BD, the median age at diagnosis was 
39.0 years and 27.5% of them were male. The rate of ANCA pos-
itivity was 2.2%: MPO-ANCA (or P-ANCA) was detected in 12 
patients, and PR3-ANCA (or C-ANCA) was noted in 6 patients. 
The most common BD-related clinical manifestations at diag-
nosis were oral ulcers (99.5%), followed by genital ulcers (79.6%). 
Vascular manifestations were observed in 52 patients (6.4%). 
The most common comorbidity at diagnosis was hypertension 
(14.4%), followed by dyslipidemia (14.0%) and diabetes melli-
tus (9.0%). Among 808 BD patients, 588 patients also fulfilled 
the 1990 ISG criteria (72.8%). During the follow-up period, the 
most common adverse outcome was GI involvement (12.4%), 
followed by ocular involvement (6.6%) and cerebrovascular 
disease (4.5%). Thirty-two patients (4.0%) and 29 patients (3.6%) 
exhibited acute coronary syndrome and DVT. Three patients 





Age at diagnosis (yr) 39.0 (17.0)
Male sex 222 (27.5)
ANCA positivity 
MPO-ANCA (or P-ANCA) 12 (1.5)
PR3-ANCA (or C-ANCA) 6 (0.7) 
MPO-ANCA (or P-ANCA) and PR3-ANCA (or C-ANCA) 0 (0)
ANCA negative 790 (97.8)  
BD-related clinical manifestation 
Oral ulcer 804 (99.5)
Genital ulcer 643 (79.6)
Ocular manifestation 344 (42.6)
Skin manifestation 565 (69.9)
Neurologic manifestation 67 (8.3)
Vascular manifestation 52 (6.4)
Pathergy test positivity 12 (1.5)
Comorbidities
Diabetes mellitus 73 (9.0)
Hypertension 116 (14.4)
Dyslipidemia 113 (14.0)
Aortic valve replacement 11 (1.4)
Percutaneous coronary intervention 11 (1.4)
Other vascular Intervention 22 (2.7)
Reclassification
1990 ISG criteria fulfilled 588 (72.8)
2014 ICBD criteria fulfilled 808 (100)
During follow-up
Poor outcomes
All-cause mortality 3 (0.6)
CVA 36 (4.5) 
ACS 32 (4.0)
DVT 29 (3.6)
GI involvement 100 (12.4)
Ocular involvement 53 (6.6)






TNF-α blockade 17 (2.1)
BD, Behçet’s disease; ICBD, International Criteria for Behçet’s Disease; 
ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; P, peri-
nuclear; PR3, proteinase 3; C, cytoplasmic; ISG, International Study Group; 
CVA, cerebrovascular accident; ACS, acute coronary syndrome; DVT, deep 
vein thrombosis; GI, gastrointestinal; TNF, tumor necrosis factor.
Values are expressed as a median (interquartile range) and number (percent-
age). 
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died during follow-up. Glucocorticoid was administered to 636 
BD patients (78.7%), while TNF-alpha blockade was provided 
to 17 patients (2.1%). 
Comparison of variables at diagnosis and follow-up 
between ANCA-positive and ANCA-negative BD 
patients based on the 2014 ICBD criteria
Among BD-related clinical manifestations at the diagnosis of 
BD, ANCA-positive BD patients exhibited vascular manifesta-
tions more frequently than ANCA-negative BD patients (22.2% 
vs. 6.1%, p=0.024). Also, among comorbidities at diagnosis, aor-
tic valve replacement was performed more often in ANCA-pos-
itive BD patients than ANCA-negative BD patients (15.4% vs. 
1.1%, p=0.023). In regard to the poor outcomes during follow 
up, DVT appeared more frequently in ANCA-positive BD pa-
tients than ANCA-negative BD (11.1% vs. 3.4%), although this 
was statistically insignificant. A larger portion of ANCA-posi-
tive BD patients had ever received azathioprine after diagno-
sis than ANCA-negative BD patients, and this also had no sta-
tistical significance (Table 2).
Comparison of the sites and patterns of vascular 
manifestations at diagnosis between ANCA-positive 
and ANCA-negative BD patients based on the 2014 
ICBD criteria
At diagnosis of BD, 52 patients out of a total of 808 BD patients 
exhibited 57 events of vascular manifestations: 4 patients among 
18 ANCA-positive BD patients had five vascular events, while 
48 patients out of a total of 790 ANCA-negative patients showed 
52 vascular events. ANCA-positive BD patients exhibited high-
er frequencies of vascular involvement in the upper extremi-
ties and visceral arteries than ANCA-negative BD patients (5.6% 
vs. 0.1%, p=0.044 and 5.6% vs. 0.1%, p=0.044) (Table 3).  
Comparison of cumulative adverse outcome-free 
survival rates between ANCA-positive and ANCA-
negative BD patients based on the 2014 ICBD criteria
Among the adverse outcomes, ANCA-positive BD patients tend-
ed to exhibit a lower cumulative DVT-free survival rate than 
ANCA-negative BD patients, although the difference was not 
statistically significant (p=0.111). ANCA positivity did not seem 
to be associated with adverse outcomes in BD patients during 
follow up (Fig. 1).
Characteristics of the 588 BD patients based on the 
1990 ISG criteria and comparisons of variables at 
diagnosis and during follow up between 
ANCA-positive and ANCA-negative BD patients
Using the above strategies, we investigated the baseline and 
follow-up characteristics of the 588 BD patients who met the 
1990 ISG criteria (Supplementary Table 2, only online). ANCA 
was detected in 13 patients out of the 588 BD patients (2.2%): 
MPO-ANCA (or P-ANCA) was detected in 8 patients and PR3-
ANCA (or C-ANCA) was recorded in 5 patients. Vascular mani-
festations were observed in 26 patients (4.4%). Among BD-re-
lated clinical manifestations at diagnosis, ANCA-positive BD 
patients exhibited a higher frequency of vascular manifestations 
than ANCA-negative BD patients (23.1% vs. 4.0%, p=0.016). 
Also, among comorbidities at diagnosis, aortic valve replace-
ment and vascular intervention, except coronary intervention, 
were performed more often in ANCA-positive BD patients than 
in ANCA-negative BD patients (15.4% vs. 0.5%, p=0.004 and 
15.4% vs. 1.6%, p=0.022). In respect to adverse outcomes dur-
ing follow up, DVT showed a tendency to develop more often 
in ANCA-positive BD patients than in ANCA-negative BD pa-
tients (15.4% vs. 3.3%), although it was not statistically signifi-
cant. There were no differences between the two groups of BD 
patients in regards to administered medications (Table 4).
Comparison of sites and pattern of vascular 
manifestations at diagnosis between ANCA-positive 
and ANCA-negative BD patients based on the 1990 
ISG criteria
At diagnosis, 26 patients out of the 588 BD patients experienced 
30 events of vascular manifestations: 3 patients among the 13 
ANCA-positive BD patients had four vascular incidents, where-
as 26 patients out of the 575 ANCA-negative patients had 26 
vascular-featured events. Compared to the results from 808 BD 
patients who met the 2014 ICBD criteria, analogous results were 
obtained from the 588 BD patients who met the 1990 ISG cri-
teria: ANCA-positive BD patients exhibited higher frequencies 
of vascular involvement in the upper extremities and visceral 
arteries than ANCA-negative BD patients (7.7% vs. 0.2%, p= 
0.044 and 7.7% vs. 0%, p=0.022) (Supplementary Table 3, only 
online).  
Comparison of the cumulative adverse outcome-free 
survival rates between ANCA-positive and ANCA-
negative BD patients based on the 1990 ISG criteria
Among the adverse outcomes we assessed, ANCA-positive BD 
patients tended to exhibit a lower cumulative DVT-free survival 
rate than ANCA-negative BD patients, but the difference was 
lacked statistical significance (p=0.050). ANCA positivity did 
not seem to be associated with adverse outcomes in BD pa-
tients during follow up, regardless of diagnosis criteria for BD 
(Fig. 2). 
DISCUSSION
In this study, we investigated whether ANCA positivity might 
be associated with cross-sectional vascular manifestations at 
diagnosis and whether ANCA positivity could be assessed to 
predict the likelihood of adverse outcomes occurring, including 
vascular complications, during follow up in patients with BD. 
First, we identified the association of ANCA positivity with vas-
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cular manifestations at diagnosis, as ANCA-positive BD patients 
exhibited a significantly higher frequency of vascular manifes-
tations than ANCA-negative BD patients, regardless of the cri-
teria for BD. In particular, we found that ANCA-positive BD pa-
tients had more vascular manifestations in the upper extremities 
and visceral arteries with higher frequencies of extra-pulmo-
nary arterial involvement than ANCA-negative BD patients. 
According to a previous study, the most common sites and 
patterns of vascular involvement at the first event in BD pa-
tients were DVT, followed by central venous thrombosis, pul-
Table 2. Comparison of Variables at Diagnosis and during Follow-Up between ANCA-Positive and ANCA-Negative BD Patients Based on the 2014 
ICBD Criteria
Variables ANCA-positive BD patients (n=18) ANCA-negative BD patients (n=790) p value
At diagnosis
Demographic data
Age (yr) 34.5 (24.0) 40.0 (17.0) 0.346
Male sex 7 (38.9) 215 (27.2) 0.273
BD-related clinical manifestation
Oral ulcer 18 (100) 786 (99.5) 1.000
Genital ulcer 12 (66.7) 631 (80.0) 0.169
Ocular manifestation 10 (55.6) 334 (42.3) 0.260
Skin manifestation 11 (61.1) 554 (70.1) 0.410
Neurologic manifestation 0 (0) 67 (8.5) 0.389
Vascular manifestation 4 (22.2) 48 (6.1) 0.024
Pathergy test positivity 1 (5.6) 11 (1.4) 0.238
Comorbidities at diagnosis
Diabetes mellitus 2 (15.4) 71 (9.0) 0.673
Hypertension 4 (30.8) 110 (13.9) 0.304
Dyslipidemia 4 (30.8) 108 (13.7) 0.297
Aortic valve replacement 2 (15.4)  9 (1.1) 0.023
Percutaneous coronary intervention 0 (0) 11 (1.4) 1.000
Other vascular Intervention 2 (15.4) 20 (2.5) 0.082
During follow-up
Follow-up duration (months) 132.0 (99.6) 113.4 (79.5) 0.624
Poor outcomes
All-cause mortality 0 (0) 3 (0.4) 1.000
Follow-up duration for death (months) 132.0 (99.6) 113.4 (79.5) 0.624
CVA 0 (0) 36 (4.6) 1.000
Follow-up duration for CVA (months) 132.0 (99.6) 112.1 (80.4) 0.494
ACS 1 (5.6)) 31 (3.9) 1.000
Follow-up duration for ACS (months) 132.0 (104.5) 112.2 (79.3) 0.574
DVT 2 (11.1) 27 (3.4) 0.075
Follow-up duration for DVT (months) 118.5 (105.7) 112.2 (80.0) 0.934
GI involvement 2 (11.1) 98 (12.4) 0.680
Follow-up duration for GI disease (months) 118.5 (105.7) 107.5 (81.2) 0.552
Ocular involvement 2 (11.1) 51 (6.4) 0.574
Follow-up duration for ocular disease (months) 132.0 (99.6) 111.2 (79.9) 0.485
Medications administered
Glucocorticoid 14 (77.8) 622 (78.7) 1.000
Colchicine 12 (66.7) 591 (74.8) 0.432
Azathioprine 8 (44.4) 180 (22.8) 0.032
Methotrexate 0 (0) 46 (5.8) 0.618
Cyclosporine 0 (0) 35 (4.4) 1.000
TNF-α blockade 0 (0) 17 (2.2) 1.000
BD, Behçet’s disease; ANCA, antineutrophil cytoplasmic antibody; ICBD, International Criteria for Behçet’s Disease; CVA, cerebrovascular accident; ACS, acute 
coronary syndrome; DVT, deep vein thrombosis; GI, gastrointestinal; TNF, tumor necrosis factor. 
Values are expressed as a median (interquartile range) and number (percentage). 
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monary arterial involvement, and extra-pulmonary arterial in-
volvement. However, as the frequency of vascular involvement 
increased, the proportion of DVT gradually decreased, where-
as extra-pulmonary arterial involvement increased.11 Since vas-
cular manifestations at diagnosis of BD were reviewed in this 
study, a frequency of extra-pulmonary arterial involvement was 
Table 3. Comparison of the Sites and Pattern of Vascular Manifestation at Diagnosis between ANCA-Positive and ANCA-Negative BD Patients Based 









Lower extremity vein thrombosis
Deep vein 13 (1.6) 0 (0) 13 (1.6) 1.000
Superficial vein 12 (1.5) 1 (5.6) 11 (1.4) 0.238
Vena cava thrombosis
Inferior vena cava 0 (0) 0 (0) 0 (0) N/A
Superior vena cava 0 (0) 0 (0) 0 (0) N/A
Cerebral venous sinus thrombosis 2 (0.2) 0 (0) 2 (0.3) 1.000
Pulmonary artery involvement 2 (0.2) 0 (0) 2 (0.3) 1.000
Intracardiac thrombosis 4 (0.5) 1 (5.6) 3 (0.4) 0.086
Aorta involvement
Aortic aneurysm 7 (0.9) 0 (0) 7 (0.9) 1.000
Carotid artery aneurysm 2 (0.2) 0 (0) 2 (0.3) 1.000
Extra-pulmonary artery involvement
Lower extremity artery 11 (1.4) 1 (5.6) 10 (1.3) 0.221
Upper extremity artery 2 (0.2) 1 (5.6) 1 (0.1) 0.044
Visceral artery 2 (0.2) 1 (5.6) 1 (0.1) 0.044
Comments N=52, E=57 N=4, E=5 N=48, E=52
Number of patients with vascular manifestation (N) and vascular events (E) 
BD, Behçet’s disease; ANCA, antineutrophil cytoplasmic antibody; ICBD, International Criteria for Behçet’s Disease; E, event.
Values are expressed as number (percentage). 
Fig. 1. Comparison of the cumulative adverse outcome-free survival rates between ANCA-positive and ANCA-negative BD patients based on the 2014 
ICBD criteria. ANCA positivity did not seem to be associated with adverse outcomes in BD patients during follow up. ANCA, antineutrophil cytoplasmic 
antibody; BD, Behçet’s disease; ICBD, the International Criteria for Behçet’s Disease; CVA, cerebrovascular accident; ACS, acute coronary syndrome; 
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theoretically expected to be lower than frequencies of DVT and 
pulmonary arterial involvement. In the present study, the most 
common vascular manifestation was DVT, as was expected, but 
vena cava involvement was not prominent. Interestingly, both 
DVT and pulmonary artery involvement were observed only in 
ANCA-negative BD patients. Nevertheless, vascular involve-
ment in the upper extremities and visceral arteries, which be-
long to extra-pulmonary arterial involvement, were found more 










Age (yr) 34.0 (24.0) 39.0 (15.0) 0.449
Male sex 7 (53.8) 165 (28.7) 0.049
Clinical manifestation 
Oral ulcer 13 (100) 575 (100) N/A
Genital ulcer 8 (61.5) 490 (85.2) 0.019
Ocular manifestation 9 (69.2) 290 (50.4) 0.262
Skin manifestation 11 (84.6) 519 (90.3) 0.373
Neurologic manifestation 0 (0) 38 (6.6) 1.000
Vascular manifestation 3 (23.1) 23 (4.0) 0.016
Pathergy test positivity 1 (7.7) 10 (1.7) 0.220
Comorbidities at diagnosis
Diabetes mellitus 2 (15.4) 51 (8.9) 0.330
Hypertension 4 (30.8) 81 (14.9) 0.104
Dyslipidemia 4 (30.8) 79 (13.7) 0.097
Aortic valve replacement 2 (15.4) 3 (0.5) 0.004
Percutaneous coronary intervention 0 (0) 10 (1.7) 1.000
Other vascular Intervention 2 (15.4) 9 (1.6) 0.022
During follow-up
Follow-up duration (months) 156.1 (108.9) 116.0 (80.0) 0.103
Poor outcomes
All-cause mortality 0 (0) 2 (0.35) 1.000
Follow-up duration for death (months) 156.1 (108.9) 116.0 (80.0) 0.103
CVA 0 (0) 27 (4.7) 1.000
Follow-up duration for CVA (months) 156.1 (108.9) 114.6 (80.0) 0.080
ACS 0 (0) 25 (4.3) 1.000
Follow-up duration for ACS (months) 156.1 (108.9) 114.7 (80.1) 0.083
DVT 2 (15.4) 19 (3.3) 0.075
Follow-up duration for DVT (months) 132.0 (151.9) 113.8 (80.3) 0.391
GI involvement 2 (15.4) 74 (12.9) 0.680
Follow-up duration for GI disease (months) 143.6 (129.4) 110.9 (81.2) 0.219
Ocular involvement 1 (7.7) 36 (6.3) 0.574
Follow-up duration for ocular disease (months) 156.1 (103.5) 113.7 (80.3) 0.077
Medications administered
Glucocorticoid 12 (92.3) 459 (79.8) 0.707
Colchicine 8 (61.5) 446 (77.6) 0.173
Azathioprine 5 (38.5) 139 (24.2) 0.236
Methotrexate 0 (0) 33 (5.7) 1.000
Cyclosporine 0 (0) 21 (3.7) 1.000
TNF-α blockade 0 (0) 9 (1.6) 1.000
BD, Behçet’s disease; ANCA, antineutrophil cytoplasmic antibody; ISG, International Study Group; CVA, cerebrovascular accident; ACS, acute coronary syn-
drome; DVT, deep vein thrombosis; GI, gastrointestinal; TNF, tumor necrosis factor. 
Values are expressed as a median (interquartile range) and number (percentage). 
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often in ANCA-positive BD patients than in ANCA-negative BD 
patients. Therefore, we speculate that ANCA might participate 
in or accelerate aneurysm and/or thrombosis in the lower ex-
tremities and visceral arteries in BD patients.
As for large-sized vessel involvement, BD can encroach large 
vessels, such as in aortic valve and/or ascending aorta involve-
ment and vena cava thrombosis, which may lead to fatal out-
comes.12,13 Although large vessel vasculitis is likely to be a con-
sequence of BD involvement, AAV can also provoke large vessel 
vasculitis: so far, several case series have reported that large 
vessel vasculitis might be associated with AAV and have indi-
cated that large vessel vasculitis can occur in a spectrum of 
various clinical features.14-16 Thus, vascular manifestations that 
characterize large vessel vasculitis in ANCA-positive BD pa-
tients are likely to contributable to both BD and AAV. In our 
study, we did not notice any ANCA-positive BD patients who 
exhibited vena cava thrombosis or aorta involvement. There-
fore, this point further supports our assumption that ANCA 
might be associated with vascular involvement in the upper 
extremities and visceral arteries in BD patients.
Secondly, a previous study reported that the incidence of ar-
terial and venous thrombosis was greater in AAV patients than 
in the corresponding age- and gender-matched non-AAV pop-
ulation, and that trend was obvious within a 1-year follow-up. 
Particularly, at baseline, MPO-ANCA was detected more often 
in AAV patients with arterial thromboembolism than those 
without (58% vs. 35%, p=0.011); however, the detection of MPO-
ANCA did not differ in AAV patients, regardless of having ve-
nous thromboembolism.17 Based on these results, although the 
disease type was different, at least at the entry of this study, we 
expected that ANCA-positive BD patients would exhibit a high-
er cumulative rate of thrombotic events than ANCA-negative 
BD patients during follow up. However, we found that ANCA 
positivity had no predictive potential on the occurrence of any 
arterial or venous thrombotic events in BD patients who met 
either the 2014 ICBD criteria or the 1990 ISG criteria.
Although the most common vascular involvement at diag-
nosis was DVT among all BD patients we investigated, DVT 
was not present in any ANCA-positive BD patients at diagno-
sis. During follow up, however, DVT occurred in 2 of 18 ANCA-
positive BD patients who met the 2014 ICBD criteria and 2 of 
13 ANCA-positive BD patients who met the 1990 ISG criteria. 
ANCA positivity tended to reduce the cumulative DVT-free sur-
vival rate, compared to ANCA negativity, in 588 BD patients 
who fulfilled the 1990 ISG criteria for BD. Nevertheless, there 
were no significant differences in the cumulative thrombotic 
event-free survival rates between ANCA-positive and ANCA-
negative BD patients. Based these results, we developed two 
hypotheses: first, ANCA positivity does not contribute to the 
occurrence of thrombotic complications in BD patients. Sec-
ond, ANCA positivity may contribute to, but does not surpass, 
the thrombotic potential of BD itself.
Since vascular involvement in BD, which is a focus of our 
current study, is one of the items in the 2014 ICBD criteria, but 
not in the 1990 ISG criteria, we applied both criteria to previ-
ously diagnosed BD patients in this study.4,5 Accordingly, we 
expected different sites and patterns of vascular involvement 
in BD patients classified based on the two different criteria; 
however, vascular involvement was similar between BD pa-
tients based on the 2014 ICBD criteria and those based on the 
1990 ISG criteria. Therefore, we could generalize our results in 
BD patients regardless of either criteria system.
In this study, we counted the number of patients who had no 
results of antigen-specific assay, but had ANCA positivity by 
Fig. 2. Comparison of the cumulative adverse outcome-free survival rates between ANCA-positive and ANCA-negative BD patients based on the 1990 
ISG criteria. ANCA positivity did not seem to be associated with adverse outcomes in BD patients during follow-up. ANCA, antineutrophil cytoplasmic an-
tibody; BD, Behçet’s disease; ISG, the International Study Group; CVA, cerebrovascular accident; ACS, acute coronary syndrome; DVT, deep vein throm-
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IIF, as ANCA-positive for two reasons: one is that the specifici-
ty of antigen-specific assay is higher than that of IIF, whereas 
its sensitivity is lower than that of IIF. Therefore, concerns over 
false-positives for ANCA of IIF and false-negatives for ANCA 
of antigen-specific assays are still raised in real clinical settings. 
Another reason is that ANCA by IIF is currently used in the clas-
sification of AAV, and we use the IIF as the primary screening 
method for ANCA. Patients who were negative for ANCA on 
antigen-specific assay but positive by IIF are considered to have 
MPO-ANCA or PR3-ANCA when AAV is strongly suspected by 
the clinical and laboratory features.18
Our study has several limitations. 1) Our study was designed 
as a retrospective study, and thus, we cannot assuage concerns 
about missing data and could not repeat ANCA tests during 
follow up. 2) The number of ANCA-positive BD patients was 
not large enough to yield more statistically significant results. 
3) Only patients who had BD as the primary diagnosis and ful-
filled either the 1990 ISG or the 2014 ICBD criteria for BD were 
included in this study; we did not include clinically suspected 
BD patients. 4) This study did not include inflammation of 
smaller vessels, such as uveitis, other than for eight categories.11 
Since ANCA may affect small vessels more often than larger 
vessels, these vascular manifestations should not be ignored. 
5) With regard to missing data of BD patients without the re-
sults of ANCA tests, because clinical data were abstracted and 
collected by a CDR system with several terms, including BD and 
ANCA results, the number and clinical characteristics of BD 
patients without ANCA results could not be obtained. 6) Since 
patients who had no results of antigen-specific assay but had 
ANCA positivity by IIF were considered to have MPO-ANCA (or 
P-ANCA) or PR3-ANCA (or C-ANCA), there might be false-pos-
itive for ANCA. However, our study has a strength, as we dem-
onstrated the clinical significance of ANCA positivity in a large 
number of BD patients for the first time. Also, we believe that 
as a pilot study, our findings will encourage researchers to fur-
ther evaluate the clinical implications of ANCA positivity in BD 
patients. In addition, future prospective studies with serial re-
sults of repeated ANCA tests will clarify the exact mechanism 
underlying the association between ANCA positivity and vas-
culitis involvement in BD.
In conclusion, the rate of ANCA positivity in BD patients was 
2.2%, and ANCA positivity at diagnosis was associated with 
cross-sectional vascular involvement in the upper extremities 
and visceral arteries. It was, however, not predictive of adverse 
outcomes during follow up.
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